Related Experiment Video
Updated: May 8, 2026

The Soft Agar Colony Formation Assay
Published on: October 27, 2014
Aflatoxin B1 negatively regulates Wnt/β-catenin signaling pathway through activating miR-33a
Yi Fang1, Youjun Feng, Tongjin Wu
1The Ministry of Education Key Laboratory of Biopesticide and Chemical Biology and the College of Life Sciences, Fujian Agriculture and Forestry University, Fuzhou, P. R. China ; Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, P. R. China ; Fujian Key Laboratory of Integrative Medicine on Geriatrics, Fujian University of Traditional Chinese Medicine, Fuzhou, P. R. China.
Abstract:
MicroRNAs are known to play an important role in modulating gene expression in various diseases including cancers and cardiovascular disorders, but only a few of them are associated with the pathology of aflatoxin B1 (AFB1), a potent mycotoxin. Here, we discovered a novel regulatory network between AFB1, miR-33a and β-catenin in human carcinoma cells. The level of miR-33a was up-regulated in hepatocellular carcinoma (HCC) cells treated with AFB1, while in the same cells causing the decrease in β-catenin expression when treated at their IC50 values. miR-33a, specifically miR-33a-5p, was demonstrated to down-regulate the expression of β-catenin, affect the β-catenin pathway, and inhibit cell growth. Also, by employing a luciferase assay, we found that miR-33a down-regulated β-catenin by directly binding to the 3'-UTR of β-catenin. These results suggested that AFB1 might down-regulate β-catenin by up-regulating miR-33a. This understanding opens new lines of thought in the potential role of miR-33a in the clinical therapy of cancer.
Insights
Aflatoxin B1 (AFB1) exposure increases microRNA-33a (miR-33a) levels, which then decrease beta-catenin expression in liver cancer cells. This novel AFB1-miR-33a-beta-catenin pathway offers potential therapeutic targets for cancer treatment.
Area of Science:
- Molecular Biology
- Cancer Research
- Toxicology
Background:
- MicroRNAs regulate gene expression in diseases like cancer.
- Aflatoxin B1 (AFB1) is a potent mycotoxin linked to various health issues.
- The role of microRNAs in AFB1-induced pathology is not well understood.
Purpose of the Study:
- To investigate the regulatory network between AFB1, miR-33a, and beta-catenin in human carcinoma cells.
- To elucidate the mechanism by which AFB1 affects beta-catenin expression.
- To explore the potential of miR-33a as a therapeutic target in cancer.
Main Methods:
- Treatment of hepatocellular carcinoma (HCC) cells with AFB1.
- Quantification of miR-33a and beta-catenin expression levels.
- Luciferase assay to confirm direct binding of miR-33a to beta-catenin.
- Analysis of the beta-catenin pathway and cell growth inhibition.
Main Results:
- AFB1 up-regulated miR-33a levels in HCC cells.
- miR-33a down-regulated beta-catenin expression and affected the beta-catenin pathway.
- miR-33a directly bound to the 3'-UTR of beta-catenin, inhibiting cell growth.
- AFB1 potentially down-regulates beta-catenin by up-regulating miR-33a.
Conclusions:
- A novel regulatory network involving AFB1, miR-33a, and beta-catenin in human carcinoma cells was discovered.
- miR-33a acts as a tumor suppressor by down-regulating beta-catenin.
- This finding provides new insights into the role of miR-33a in cancer therapy.
Related Concept Videos
Canonical Wnt Signaling Pathway
Canonical Wnt Signaling Pathway
Non-Canonical Wnt Signaling Pathways
Non-Canonical Wnt Signaling Pathways
Catenins
Catenins in Cell Junctions
Catenins bind to cell adhesion molecules such as cadherins and link them to different cytoskeletal proteins depending on the type of cell junction. At the adherens...
TGF - β Signaling Pathway